SHANGHAI – Bristol-Myers Squibb Co.'s Opdivo (nivolumab) has become the first PD-1 inhibitor to be approved for patients in China, in a classic example that China' drug lag is real. Chinese lung patients will have access to the cutting edge immuno-oncology (I-O) therapy four years after it was first approved in the U.S. and after it has been approved in 60 countries.